JPRN-C000000448已完成2 期
A phase II study of Irinotecan (CPT-11) for Leiomyosarcoma of Uterus - A phase II study of Irinotecan (CPT-11) for Leiomyosarcoma of Uterus
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients with previous CPT-11 chemotherapy. 2) Patients with any history of serious drug reactions or hypersensitivity to CPT-11 3) Patients with massive pleural, cardiac effusion, and/or ascites 4) Patients with symptomatic brain metastasis 5) Patients with active infections 6) Patients with diarrhea (watery stool) five times or more in a day 7) Patients with unstable angina, history of cardiac infarction within 6 months, or arrhythmia that requires medical treatment 8) Patients with intestinal paralysis or illeus 9) Patients with interstitial pneumonia or pulmonary fibrosis 10) Patients with active concomitant malignancy. * Patients with history of any other malignancy within 5 years are ineligible. * Patients with carcinoma in situ or intramucosal malignancy that was curable with local therapy are eligible. 11) Patients with uncontrolled diabetes mellitus 12) Patients who are under the treatment with Atzanavir 13) Patients during pregnancy or breast-feeding, or unwilling to the use of contraception 14) Patients who are inappropriate to enter this study with any safety reasons, judged by the treating physician
研究者
相似试验
已完成
2 期
Randomized phase II trial of irinotecan(CPT-11) plus tegafur/uracil with oral leucovorin(UFT/LV) compared with FOLFIRI in patients with unresectable/recurrent colorectal cancerPatients with previously untreated and unresectable/recurrent colorectal cancerJPRN-UMIN000000951Department of Surgery, School of Medicine, Keio University72
进行中（未招募）
1 期
Clinical study of irinotecan weekly in patients with locally advanced or metastatic HER2-negative breast cancer and increased cancer cell copy number of the topoisomerase 1 gene”MedDRA version: 17.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic breast cancerEUCTR2012-002348-26-DKDanish Breast Cancer Group (BDCG)40
已完成
1 期
A multicenter phase I/II study of irinotecan (CPT-11) and S-1 combination chemotherapy for metastatic colorectal cancer (CRC)advanced/recurrent colorectal cancerJPRN-UMIN000001617CPT-11/TS-1 study group30
进行中（未招募）
不适用
A clinical trial to compare tolerabilty and efficiacy (how well the drug works) of following treatments:Blocking liver arteries (chemoembolisation) by beads loaded with irinotecan (chemotherapeutic) and intravenous administration of cetuximab (chemotherapeutic) compared to administration of intravenous cetuximab and irinotecan in patients with k-ras (gene) wild-type tumors.Patients with unresectable liver metastases of colorectal cancer who previously failed pretreatment with 5FU/oxaliplatin and/or 5FU/irinotecan (2nd- or 3rd-line).MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014728-44-DEMartin Luther Universität Halle-Wittenberg80
已完成
2 期
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Panitumumab as second line treatment in patients with KRAS wild type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009317Yamaguchi University Department of Digestive Surgery and Surgical Oncology30